Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma
Matthew J. Maurer(Mayo Clinic in Arizona), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Jonathon B. Cohen(Emory University), Thomas M. Habermann(Mayo Clinic in Arizona), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Peter Martin(Northwestern University), Anthony Masaquel, Izidore S. Lossos(University of Miami), Dai Chihara(The University of Texas MD Anderson Cancer Center), Ashwini Shewade, Carla Casulo(University of Rochester Medical Center), Michael C. Wei(The Royal Melbourne Hospital), Brad S. Kahl(UW Health University Hospital), James R. Cerhan(Mayo Clinic), Brian K. Link(University of Iowa), Jean L. Koff(Emory University), Mei Wu(Nanfang Hospital), Li Jia(Shanghai Institutes for Biological Sciences), Yucai Wang(Mayo Clinic), Melissa C. Larson(Mayo Clinic), Christopher Strouse(University of Iowa Hospitals and Clinics), Yong Mun, Richard Burack(University of Rochester Medical Center)
Cited by 8
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Body-Mass Index and Mortality among 1.46 Million White Adults
|New England Journal of Medicine|2010|2.3k